LncRNA EBLN3P Accelerates Cell Proliferation and Invasion of Colon Cancer through Modulating the miR-519d-3p/ZFP91 Axis
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2022.0089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Xiaohui Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Bayinguoleng Mongolian Autonomous Prefecture People's Hospital, Korla, People's Republic of China. Hauptthemen laut MEDLINE: MicroRNAs, Colonic Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Bayinguoleng Mongolian Autonomous Prefecture People's Hospital, Korla, People's Republic of China.
- Department of General Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, People's Republic of China.
- Department of Anorectal Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, People's Republic of China.
ORCID-Profile: Shuai Yan
Zitieren
APA
Wang, X., Yue, Y., Tan, J., Kou, F., Su, B., Xie, J., & Yan, S. (2024). LncRNA EBLN3P Accelerates Cell Proliferation and Invasion of Colon Cancer through Modulating the miR-519d-3p/ZFP91 Axis. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2022.0089
Vancouver
Wang X, Yue Y, Tan J, Kou F, Su B, Xie J, et al. LncRNA EBLN3P Accelerates Cell Proliferation and Invasion of Colon Cancer through Modulating the miR-519d-3p/ZFP91 Axis. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2022.0089
BibTeX
@article{Wang2024,
author = {Wang, Xiaohui and Yue, Yinzi and Tan, Jinhua and Kou, Fei and Su, Bude and Xie, Jin and Yan, Shuai},
title = {LncRNA EBLN3P Accelerates Cell Proliferation and Invasion of Colon Cancer through Modulating the miR-519d-3p/ZFP91 Axis},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2022.0089}
}
EUVIMED